|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2001-3-8
|
|
pubmed:abstractText |
The use of autologous peripheral blood progenitor cells (PBPC) expedites hematologic recovery and reduces the costs of transplantation in comparison with autologous bone marrow; however, its efficacy in patients with Hodgkin's disease has been questioned. We evaluated the results of autologous PBPC transplantation in a population of unselected and uniformly treated patients with primary refractory or relapsed Hodgkin's disease.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
665-72
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:10942053-Adolescent,
pubmed-meshheading:10942053-Adult,
pubmed-meshheading:10942053-Antigens, CD34,
pubmed-meshheading:10942053-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10942053-Carmustine,
pubmed-meshheading:10942053-Combined Modality Therapy,
pubmed-meshheading:10942053-Cytarabine,
pubmed-meshheading:10942053-Disease-Free Survival,
pubmed-meshheading:10942053-Etoposide,
pubmed-meshheading:10942053-Female,
pubmed-meshheading:10942053-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:10942053-Hodgkin Disease,
pubmed-meshheading:10942053-Humans,
pubmed-meshheading:10942053-L-Lactate Dehydrogenase,
pubmed-meshheading:10942053-Male,
pubmed-meshheading:10942053-Melphalan,
pubmed-meshheading:10942053-Middle Aged,
pubmed-meshheading:10942053-Prognosis,
pubmed-meshheading:10942053-Recurrence,
pubmed-meshheading:10942053-Transplantation, Autologous
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease.
|
|
pubmed:affiliation |
Section of Medical Oncology, Yale University-School of Medicine, New Haven, Connecticut 06520, USA. athanassios@pol.net
|
|
pubmed:publicationType |
Journal Article
|
